MERCK Kommanditgesellschaft auf Aktien: insider trades · Germany · BaFin

About MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien (ISIN: DE0006599905, ticker: MRK.DE) is a benchmark German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. Merck positions itself as a science and technology group with three core business pillars: Life Science, Healthcare, and Electronics. Founded in 1668, it is one of Germany’s oldest industrial groups, headquartered in Darmstadt, where the company’s global decision-making center is also located. The founding family remains the long-term anchor shareholder, supporting a governance model built around continuity and strategic patience. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/grundlagen-des-konzerns/unternehmensprofil-und-struktur.html?utm_source=openai)) Operationally, Merck spans human healthcare, tools and services for biopharma research and production, and high-performance materials for semiconductors and advanced electronics. In Healthcare, the group markets therapies and products in oncology, cardiovascular disease, metabolic disorders, and endocrinology; Erbitux remains one of the segment’s leading products by sales. Life Science serves laboratories, bioprocessing customers, and biotech manufacturers with consumables, reagents, filtration and quality-control solutions, alongside process-development services. Electronics supplies specialty materials and process solutions for displays, semiconductor manufacturing, and other high-end technology applications. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/wirtschaftsbericht/vergleich-prognose-mit-geschaeftsverlauf.html?utm_source=openai)) Merck’s competitive position is grounded in scientific depth, global reach, and exposure to long-term growth markets. In healthcare, it competes with major global pharma groups but benefits from a focused portfolio and a strong innovation engine. In Life Science, Merck has a well-established customer base across biopharma thanks to a broad, hard-to-replicate product and services platform. Electronics is more cyclical, but it gives the group leverage to semiconductor and advanced materials demand trends. The group reported a return to growth in 2024, with consolidated revenue of EUR 21.156 billion. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/wirtschaftsbericht/geschaeftsverlauf-und-wirtschaftliche-lage/konzern.html?utm_source=openai)) Recent headlines highlight active portfolio management. In February 2025, Merck confirmed advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, underscoring its intent to deepen its Healthcare footprint. In 2024, the group also announced the divestment of Surface Solutions, with closing expected in the second half of 2025, as part of a sharpening of Electronics around more strategic businesses. At the same time, Merck continued to invest in production and R&D capabilities in Germany and South Korea, reinforcing its global industrial and innovation base. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/konzernanhang/allgemeine-angaben/ereignisse-nach-dem-bilanzstichtag.html?utm_source=openai))